François‐Clément Bidard

Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data

François‐Clément Bidard, Dieter Peeters, Tanja Fehm et al. · The Lancet Oncology · 2014 · 838 citations

Medicine, Cancer Biology, Oncology +17

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

François‐Clément Bidard, Virginia Kaklamani, Patrick Neven et al. · Journal of Clinical Oncology · 2022 · 695 citations · Full text

Medicine, Oncology, Pharmacology +15

ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group

Javier Pascual, Gerhardt Attard, François‐Clément Bidard et al. · Annals of Oncology · 2022 · 664 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle

Leticia De Mattos‐Arruda, Britta Weigelt, Javier Cortés et al. · Annals of Oncology · 2014 · 378 citations · Full text

Medicine, Genetics, Oncology +16

Circulating Tumor Cell Detection Predicts Early Metastatic Relapse After Neoadjuvant Chemotherapy in Large Operable and Locally Advanced Breast Cancer in a Phase II Randomized Trial

Jean‐Yves Pierga, François‐Clément Bidard, Claire Mathiot et al. · Clinical Cancer Research · 2008 · 370 citations

Medicine, Oncology, Breast Oncology +16